Stocks Health care ZLAB
NASDAQ · Health careZai Lab Ltd (ZLAB)
Zai Lab Ltd brought in $441.7M of revenue over the twelve months to September 30, 2026, up 0.0% from a year earlier. It posted a net loss of $198.4M. In fiscal 2025 capital spending exceeded operating cash flow by $158.9M. At September 30, 2026 it held $549.7M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on November 5, 2026.
Key facts about Zai Lab Ltd
- Net worth
- Zai Lab Ltd has a market value (market cap) of $2.9B at the latest share price, and shareholders' equity of $563.3M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $460.2M (+15.3% year on year), with a net loss of $175.5M. Over the 12 months to September 30, 2026: revenue $441.7M, net loss $198.4M.
- Cash flow
- In fiscal 2025 operations used $150.8M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on November 5, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
- Next earnings report
- Zai Lab Ltd's next report is expected around February 25, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
What Zai Lab Ltd does
Zai Lab Ltd is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker ZLAB.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $460.2M | -$175.5M | -$0.16 | -$158.9M |
| 2024 | $399M | -$257.1M | -$0.26 | -$220.5M |
| 2023 | $266.7M | -$334.6M | -$0.35 | -$205.4M |
| 2022 | $215M | -$443.3M | -$0.46 | -$392.2M |
| 2021 | $144.3M | -$704.5M | -$0.76 | -$567.5M |
| 2020 | $49M | -$268.9M | -$0.35 | -$226.2M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where ZLAB ranks in Health care
Latest SEC filings
What Zai Lab Ltd has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 5, 2026Quarterly report 10-Q · period to September 30, 2026Revenue fell 6.8% to $108.2M versus the same quarter last year; diluted EPS -$0.04 versus -$0.03.
- November 5, 2026
- October 23, 2026
- August 6, 2026Quarterly report 10-Q · period to June 30, 2026Revenue fell 3.3% to $106.3M versus the same quarter last year; diluted EPS -$0.05 versus -$0.04.
- August 6, 2026
- June 17, 2026
- June 11, 2026Passive stake (5% or more) SCHEDULE 13G
- May 21, 2026
- May 7, 2026Quarterly report 10-Q · period to March 31, 2026Revenue fell 6.5% to $99.6M versus the same quarter last year; diluted EPS -$0.05 versus -$0.04.
- May 7, 2026
Insider trades
What the people running Zai Lab Ltd did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders sold $7K worth of shares in the last 90 days and bought none on the open market. All of the selling was pre-planned under Rule 10b5-1 trading plans.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| October 1, 2026 | Chen YajingChief Financial Officer | Exercised options | 920 | - |
| October 1, 2026 | Chen YajingChief Financial Officer | Shares withheld for tax | 315 | $8K |
| August 19, 2026 | Chen YajingChief Financial Officer | Soldpre-planned (10b5-1) | 260 | $7K |
| August 14, 2026 | Chen YajingChief Financial Officer | Exercised options | 1,250 | - |
| August 14, 2026 | Chen YajingChief Financial Officer | Shares withheld for tax | 427 | $11.1K |
| August 12, 2026 | Lis WilliamDirector | Soldpre-planned (10b5-1) | 8,506 | $212.7K |
| August 11, 2026 | Chen YajingChief Financial Officer | Soldpre-planned (10b5-1) | 619 | $15.5K |
| July 2, 2026 | Du YingChairperson & CEO, Director | Exercised options | 11,048 | - |
Who owns ZLAB
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| RTW Investments, LP13G, passive with 1 related filers | 6.3% | February 17, 2026 |
| Chen Yu13G, passive with 4 related filers | 5.3% | June 11, 2026 |
| RA Capital Management, L.P.13G, passive with 3 related filers | 5.2% | April 6, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 93 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| Rtw Investments, LP | 6,574,032 | 0 |
| TCG Crossover Management, LLC | 6,137,627 | new |
| RA Capital Management, L.P. | 5,743,533 | +36,271 |
| ADAR1 Capital Management, LLC | 3,369,034 | +1,943,667 |
| Fmr LLC | 2,815,214 | +1,552,823 |
| Goldman Sachs Group Inc | 2,315,480 | +2,204,893 |
| Woodline Partners LP | 2,207,293 | new |
| Frazier Life Sciences Management, L.P. | 1,902,320 | 0 |
| Bamco Inc | 1,623,694 | -34,624 |
| Two Sigma Investments, LP | 1,299,394 | +989,671 |
| Citadel Advisors LLC | 1,284,706 | -403,926 |
| Rock Springs Capital Management LP | 814,707 | 0 |
| BlackRock, Inc. | 664,462 | -200,684 |
| Jane Street Group, LLC | 476,541 | +208,615 |
| B Group, Inc. | 450,646 | 0 |
| Nantahala Capital Management, LLC | 400,000 | new |
| Schroder Investment Management Group | 393,167 | 0 |
| Nan Fung Trinity (HK) Ltd | 346,466 | 0 |
| Aberdeen Group plc | 311,294 | +73,555 |
| Citigroup Inc | 300,775 | +299,816 |
Insiders
13 insiders reported holding 2,444,501 shares in total, about $64.1M at the last price.
| Holder | Shares |
|---|---|
| Du YingChairperson & CEO, Director | 1,221,401 |
| Wirth PeterDirector | 416,121 |
| Diekman John DDirector | 122,140 |
| Smiley Joshua LSee Remarks | 117,602 |
| Leung NisaDirector | 96,297 |
| Moulder Leon O JrDirector | 94,973 |
| Gaynor RichardDirector | 80,737 |
| Vounatsos MichelDirector | 72,787 |
| Amado RafaelSee Remarks | 57,022 |
| Morrison Scott WDirector | 56,904 |
Questions about ZLAB
What does Zai Lab Ltd do?
Zai Lab Ltd is a company in the Health care sector, listed on NASDAQ as ZLAB. Its shares trade on NASDAQ under the ticker ZLAB.
What is Zai Lab Ltd's net worth?
Zai Lab Ltd has a market value (market cap) of $2.9B at the latest share price, and shareholders' equity of $563.3M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Zai Lab Ltd profitable?
No. Over the twelve months to September 30, 2026 it reported a net loss of $198.4M on revenue of $441.7M.
How much revenue does Zai Lab Ltd make?
Over the twelve months to September 30, 2026 Zai Lab Ltd reported revenue of $441.7M. That is 0.0% more than a year earlier.
When did Zai Lab Ltd last report?
Its most recent periodic report is the quarterly report (10-Q) filed on November 5, 2026. It covers the period to September 30, 2026.
When is Zai Lab Ltd's next earnings report?
Zai Lab Ltd's next report is expected around February 25, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare ZLAB with
Follow ZLAB
Get an email when Zai Lab Ltd files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Zai Lab Ltd tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.